Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer

By rosaguerrero • July 20, 2022

Shin DS, Park K, Garon E, Dubinett S. Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer. Semin Oncol. 2022 Jul 2:S0093-7754(22)00045-8. doi: 10.1053/j.seminoncol.2022.06.005. Epub ahead of print. PMID: 35851153.

Tags: EZH2, Hematology/Oncology, immunotherapy, Lung cancer, PD-1 blockade, PRC2, Pulmonary, Critical Care & Sleep Medicine, Veterans Administration

Ciprofloxacin and Metronidazole As Rare Culprits of Drug-Induced Immune Thrombocytopenia in the Setting of Diverticulitis Treatment

Tai JW, Young EH, Shah VD, Reed JP. Ciprofloxacin and Metronidazole As Rare Culprits of Drug-Induced Immune Thrombocytopenia in the Setting of Diverticulitis Treatment. Cureus.[...]

Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells

Li YR, Li Z, Zhu Y, Li M, Chen Y, Lee D, Ochoa CJ, Singh T, DiBernardo G, Guo W, Li S, Zhou Y, Yu[...]

Evaluating Asparaginase Toxicity in Hispanic Patients With Acute Lymphoblastic Leukemia in a Large Safety-Net Hospital

Zheng D, Dragan M, Jang J, Tomassetti S. Evaluating Asparaginase Toxicity in Hispanic Patients With Acute Lymphoblastic Leukemia in a Large Safety-Net Hospital. World J[...]